Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

Boehringer Ingelheim and Veeva (VEEV) Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) led by Dr. Andrés Hidalgo has discovered a specialized population of neutrophils in the skin that produce extracellular matrix, ...

(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

In a report released on March 27, Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $135.00. The company’s shares ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Professor Dennis Agbonlahor, former Vice-Chancellor of Ambrose Alli University, AAU, Ekpoma, has lamented that out of the 40 molecular diagnostic laboratories established in the country during the ...

ConfirmTkt, India's leading online train-utility and ticketing platform, has renewed its association with Royal Challengers ...

today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney's ongoing ...